Regenerative Medical Technology Group Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Regenerative Medical Technology Group Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $4.11M | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | $2.41M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $1.53M | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | $437.9K | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | $55.1K | May 5, 2022 |
| FY2020 | Dec 31, 2019 | $30.1K | Apr 13, 2021 |
| FY2019 | Dec 31, 2018 | $50.1K | Dec 9, 2020 |
| FY2018 | Dec 31, 2017 | $29.2K | Apr 17, 2019 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $2.82M | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | $1.68M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $877.0K | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | $150.1K | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | $11.1K | May 5, 2022 |
| FY2020 | Dec 31, 2019 | ($25.4K) | Apr 13, 2021 |
| FY2019 | Dec 31, 2018 | ($18.2K) | Dec 9, 2020 |
| FY2018 | Dec 31, 2017 | $24.4K | Apr 17, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($5.56M) | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | ($9.81M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($5.51M) | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | ($12.88M) | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | ($5.90M) | May 5, 2022 |
| FY2020 | Dec 31, 2019 | ($2.51M) | Apr 13, 2021 |
| FY2019 | Dec 31, 2018 | ($2.06M) | Dec 9, 2020 |
| FY2018 | Dec 31, 2017 | ($377.0K) | Apr 17, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $81.2K | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | ($715.2K) | Apr 15, 2025 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $8.20M | Apr 14, 2023 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $850.7K | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | ($419.2K) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($1.11M) | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | ($9.88M) | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | ($322.7K) | May 5, 2022 |
| FY2020 | Dec 31, 2019 | ($362.3K) | Apr 13, 2021 |
| FY2019 | Dec 31, 2018 | ($244.6K) | Dec 9, 2020 |
| FY2018 | Dec 31, 2017 | ($6.1K) | Apr 17, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $215.4K | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | $385.6K | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $198.4K | Apr 15, 2024 |
| FY2019 | Dec 31, 2018 | $4.0K | Dec 9, 2020 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $3.82M | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | $2.88M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $8.08M | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | $9.31M | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | $219.7K | May 5, 2022 |
| FY2020 | Dec 31, 2019 | $26.4K | Apr 13, 2021 |
| FY2019 | Dec 31, 2018 | $34.6K | Dec 9, 2020 |
| FY2018 | Dec 31, 2017 | $7.9K | Apr 17, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $31.18M | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | $24.67M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $20.06M | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | $16.06M | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | $6.55M | May 5, 2022 |
| FY2020 | Dec 31, 2019 | $7.30M | Apr 13, 2021 |
| FY2019 | Dec 31, 2018 | $4.57M | Dec 9, 2020 |
| FY2018 | Dec 31, 2017 | $2.57M | Apr 17, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($27.36M) | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | ($21.80M) | Apr 15, 2025 |
| FY2024 | Dec 31, 2022 | ($11.98M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2021 | ($6.76M) | Apr 15, 2024 |
| FY2022 | Dec 31, 2020 | ($6.41M) | Apr 14, 2023 |
| FY2020 | Dec 31, 2019 | ($7.36M) | Apr 13, 2021 |
| FY2020 | Dec 31, 2018 | ($4.54M) | Apr 13, 2021 |
| FY2018 | Dec 31, 2017 | ($2.56M) | Apr 17, 2019 |
| FY2018 | Dec 31, 2016 | ($5.51M) | Apr 17, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $1.68M | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | $1.68M | Apr 15, 2025 |
| FY2024 | Dec 31, 2022 | $5.81M | Apr 15, 2025 |
| FY2023 | Dec 31, 2021 | $5.81M | Apr 15, 2024 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($67.55M) | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | ($61.99M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($52.18M) | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | ($46.67M) | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | ($33.79M) | May 5, 2022 |
| FY2020 | Dec 31, 2019 | ($27.89M) | Apr 13, 2021 |
| FY2019 | Dec 31, 2018 | ($25.38M) | Dec 9, 2020 |
| FY2018 | Dec 31, 2017 | ($23.32M) | Apr 17, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $530.5K | Apr 15, 2024 |
| FY2023 | Dec 31, 2022 | $1.65M | Apr 15, 2024 |
| FY2021 | Dec 31, 2021 | $2.98M | May 5, 2022 |
| FY2021 | Dec 31, 2020 | $42.5K | May 5, 2022 |
| FY2020 | Dec 31, 2019 | $23.4K | Apr 13, 2021 |
| FY2020 | Dec 31, 2018 | $30.8K | Apr 13, 2021 |
| FY2019 | Dec 31, 2017 | $7.8K | Dec 9, 2020 |
| FY2018 | Dec 31, 2016 | $6.6K | Apr 17, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 0 | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | 0 | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | 0 | May 5, 2022 |
| FY2019 | Dec 31, 2019 | 0 | Dec 9, 2020 |
| FY2019 | Dec 31, 2018 | 0 | Dec 9, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 0 | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | 0 | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Apr 14, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 12.54M | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | 12.49M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | 12.44M | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | 12.09M | Apr 14, 2023 |
| FY2020 | Dec 31, 2020 | 10.87M | Apr 13, 2021 |
| FY2020 | Dec 31, 2019 | 7.96M | Apr 13, 2021 |
| FY2019 | Dec 31, 2018 | 4.90M | Dec 9, 2020 |
| FY2018 | Dec 31, 2017 | 3.74M | Apr 17, 2019 |